Immunization with cross-conserved H1N1 influenza CD4+T-cell epitopes lowers viral burden in HLA DR3 transgenic mice

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 10, 2013, Pages 2060-2068

  Moise, Leonard ^a   Tassone, Ryan ^a   Latimer, Howard ^a   Terry, Frances ^a   Levitz, Lauren ^a   Haran, John P ^c   Ross, Ted M ^d   Boyle, Christine ^a   Martin, William D ^a   De Groot, Anne S ^a,b  

^a EpiVax Inc   (United States)

^b UNIVERSITY OF RHODE ISLAND   (United States)

^c BROWN UNIVERSITY   (United States)

^d Vaccine and Gene Therapy Institute of Florida   (United States)

Author keywords

Immunoinformatics; Influenza; Pandemic; T cell epitope; Vaccine

Indexed keywords

GAMMA INTERFERON; HLA DR3 ANTIGEN; INFLUENZA VACCINE; PLACEBO;

2009 H1N1 INFLUENZA; ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS PRESENTATION; CYTOKINE PRODUCTION; DRUG EFFICACY; FEMALE; FLU LIKE SYNDROME; HUMAN; HUMAN CELL; INFECTION PREVENTION; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; SEASONAL INFLUENZA; VIRUS LOAD; VIRUS STRAIN;

IMMUNOINFORMATICS; INFLUENZA; PANDEMIC; T-CELL EPITOPE; VACCINE;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; EPITOPES, T-LYMPHOCYTE; HLA-DR3 ANTIGEN; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; LUNG; MICE; MICE, TRANSGENIC; VIRAL LOAD;

EID: 84885147822     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.26511     Document Type: Article

References (32)

1. Perrone LA, Ahmad A, Veguilla V, Lu X, Smith G, Katz JM, Pushko P, Tumpey TM. Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge. J Virol 2009;83:5726-34; PMID:19321609; http://dx.doi.org/10.1128/JVI.00207-09
2. rd, Brown SA, Rehg J, Thomas PG, Webby RJ. Contemporary seasonal influenza A (H1N1) virus infection primes for a more robust response to split inactivated pandemic influenza A (H1N1) Virus vaccination in ferrets. Clin Vaccine Immunol 2010;17:1998-2006; PMID:20962210; http://dx.doi.org/10.1128/CVI.00247-10
3. Bright RA, Carter DM, Crevar CJ, Toapanta FR, Steckbeck JD, Cole KS, Kumar NM, Pushko P, Smith G, Tumpey TM, et al. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS One 2008;3:e1501; PMID:18231588; http://dx.doi.org/10. 1371/journal.pone. 0001501
4. Laurie KL, Carolan LA, Middleton D, Lowther S, Kelso A, Barr IG. Multiple infections with seasonal influenza A virus induce cross-protective immunity against A (H1N1) pandemic influenza virus in a ferret model. J Infect Dis 2010;202:1011-20; PMID:20715930; http://dx.doi.org/10.1086/656188
5. Pearce DC, Pallaghy PK, McCaw JM, McVernon J, Mathews JD. Understanding mortality in the 1918-1919 influenza pandemic in England and Wales. Influenza Other Respi Viruses 2011;5:89-98; PMID:21306572; http://dx.doi.org/10.1111/j. 1750-2659.2010.00186.x
6. Gaydos JC, Top FH Jr., Hodder RA, Russell PK Swine influenza a outbreak, Fort Dix, New Jersey, 1976. Emerg Infect Dis 2006;12:23-8; PMID:16494712; http://dx.doi.org/10.3201/eid1201.050965
7. Greenbaum JA, Kotturi MF, Kim Y, Oseroff C, Vaughan K, Salimi N, Vita R, Ponomarenko J, Scheuermann RH, Sette A, et al. Pre-existing immunity against swine-origin HI N1 influenza viruses in the general human population. Proc Natl Acad Sci USA 2009;106:20365-70; PMID:19918065; http://dx.doi.org/10.1073/pnas. 0911580106
8. Garcia-Garcia L, Valdespino-Gómez JL, Lazcano-Ponce E, Jimenez-Corona A, Higuera-Iglesias A, Cruz-Hervert P, Cano-Arellano B, Garcia-Anaya A, Ferreira-Guerrero E, Baez-Saldana R, et al. Partial protection of seasonal trivalent inactivated vaccine against novel pandemic influenza A/H1N1 2009: case-control study in Mexico City. BMJ 2009;339:b3928; PMID:19808768; http://dx.doi.org/10.1136/bmj.b3928
9. De Groot AS, Ardito M, McClaine EM, Moise L, Martin WD. Immunoinformatic comparison of T-cell epitopes contained in novel swine-origin influenza A (H1N1) virus with epitopes in 2008-2009 conventional influenza vaccine. Vaccine 2009;27:5740-7; PMID:19660593; http://dx.doi.org/10.1016/j.vaccine.2009.07.040
10. Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, Balish A, Sessions WM, Xu X, Skepner E, Deyde V, et al. Antigenic and genetic characteristics of swine-origin 2009 A (H1N1) influenza viruses circulating in humans. Science 2009;325:197-201; PMID: 19465683; http://dx.doi.org/10.1126/science.1176225
11. Moise L, Terry F, Ardito M, Tassone R, Latimer H, Boyle C, Martin WD, De Groot AS. Universal H1N1 influenza vaccine development: Identification of consensus class II hemagglutinin and neuraminidase epitopes derived from strains circulating between 1980 and 2011. [Epub ahead of print]. Hum Vaccin Immunother 2013;9; PMID=23846304; http://dx.doi.org/10.4161/hv.25598
12. Rotzschke O, Falk K, Deres K, Schild H, Norda M, Metzger J, Jung G, Rammensee HG. Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells. Nature 1990;348:252-4; PMID: 1700304; http://dx.doi.org/10.1038/348252a0
13. *0301 (DR3) gene. J Exp Med 1996;184:1167-72; PMID:9064334; http://dx.doi.org/10.1084/jem.184.3.1167
14. Co MD, Orphin L, Cruz J, Pazoles P, Green KM, Potts J, Leporati AM, Babon JA, Evans JE, Ennis FA, et al. In vitro evidence that commercial influenza vaccines are not similar in their ability to activate human T cell responses. Vaccine 2009;27:319-27; PMID: 18977404; http://dx.doi.org/10.1016/j.vaccine. 2008.09.092
15. Lee LY, Ha LA, Simmons C, De Jong MD, Chau NV, Schumacher R, Peng YC, McMichael AJ, Farrar JJ, Smith GL, et al. Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. J Clin Invest 2008;118:3478-90; PMID:18802496
16. Yewdell JW, Bennink JR, Smith GL, Moss B. Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes. Proc Natl Acad Sci U S A 1985;82:1785-9; PMID:3872457; http://dx.doi.org/10.1073/pnas.82.6.1785
17. Epstein SL, Lo CY, Misplon JA, Bennink JR. Mechanism of protective immunity against influenza virus infection in mice without antibodies. J Immunol 1998;160:322-7; PMID:9551987
18. Price GE, Soboleski MR, Lo CY, Misplon JA, Pappas C, Houser KV, Tumpey TM, Epstein SL. Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses. Vaccine 2009;27:6512-21; PMID: 19729082; http://dx.doi.0rg/10.1016/j.vaccine.2009.08.053
19. Alexander J, Bilsel P, Del Guercio MF, Stewart S, Marinkovic-Petrovic A, Southwood S, Crimi C, Vang L, Walker L, Ishioka G, et al. Universal influenza DNA vaccine encoding conserved CD4+ T cell epitopes protects against lethal viral challenge in HLA-DR transgenic mice. Vaccine 2010;28:664-72; PMID:19895924; http://dx.doi.org/10.1016/j.vaccine.2009.10.103
20. Richards KA, Topham D, Chaves FA, Sant AJ. Cutting edge: CD4 T cells generated from encounter with seasonal influenza viruses and vaccines have broad protein specificity and can directly recognize naturally generated epitopes derived from the live pandemic H1N1 virus. J Immunol 2010;185:4998-5002; PMID:20889549; http://dx.doi.org/10.4049/jimmunol.1001395
21. Tu W, Mao H, Zheng J, Liu Y, Chiu SS, Qin G, Chan PL, Lam KT, Guan J, Zhang L, et al. Cytotoxic T lymphocytes established by seasonal human influenza cross-react against 2009 pandemic H1N1 influenza virus. J Virol 2010;84:6527-35; PMID:20410263; http://dx.doi.org/10.1128/JVI.00519-10
22. Ge X, Tan V, Bollyky PL, Standifer NE, James EA, Kwok WW. Assessment of seasonal influenza A virusspecific CD4 T-cell responses to 2009 pandemic H1N1 swine-origin influenza A virus. J Virol 2010;84:3312-9; PMID:20071564; http://dx.doi.org/10.1128/JVI.02226-09
23. Ellebedy AH, Ducatez MF, Duan S, Stigger-Rosser E, Rubrum AM, Govorkova EA, Webster RG, Webby RJ. Impact of prior seasonal influenza vaccination and infection on pandemic A (H1N1) influenza virus replication in ferrets. Vaccine 2011;29:3335-9; PMID:20840835; http://dx.doi.org/10.1016/j.vaccine.2010.08.067
24. Krammer F, Palese P. Influenza virus hemagglutinin stalk-based antibodies and vaccines. Curr Opin Virol 2013; pii: S1879-6257; PMID:23978327
25. Throsby M, Van Den Brink E, Jongeneelen M, Poon LL, Alard P, Cornelissen L, Bakker A, Cox F, Van Deventer E, Guan Y, et al. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS One 2008;3:e3942; PMID:19079604; http://dx.doi.org/10.1371/journal.pone.0003942
26. Corti D, Voss J, Gamblin SJ, Codoni G, Macagno A, Jarrossay D, Vachieri SG, Pinna D, Minola A, Vanzetta F, et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 2011;333:850-6; PMID:21798894; http://dx.doi.org/10.1126/science.1205669
27. rd. Coupling sensitive in vitro and in silico techniques to assess cross-reactive CD4 (+) T cells against the swine-origin HI N1 influenza virus. Vaccine 2011;29:3299-309; PMID:21349362; http://dx.doi.org/10.1016/j.vaccine.2011.02.019
28. Steere AC, Klitz W, Drouin EE, Falk BA, Kwok WW, Nepom GT, Baxter-Lowe LA. Antibiotic-refractory Lyme arthritis is associated with HLA-DR molecules that bind a Borrelia burgdorferi peptide. J Exp Med 2006;203:961-71; PMID:16585267; http://dx.doi.org/10.1084/jem.20052471
29. Southwood S, Sidney J, Kondo A, Del Guercio MF, Appella E, Hoffman S, Kubo RT, Chesnut RW, Grey HM, Sette A. Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol 1998;160:3363-73; PMID:9531296
30. De Groot AS, Marcon L, Bishop EA, Rivera D, Kutzler M, Weiner DB, Martin W. HIV vaccine development by computer assisted design: the GAIA vaccine. Vaccine 2005;23:2136-48; PMID: 15755584; http://dx.doi.org/10.1016/j.vaccine. 20 05.01.097
31. FDA Center for Biologies Evaluation and Research (CBER). Points to Consider on Plasmid DNA Vaccines for Preventive Infectious Diseases Indications. (Docket no. 96N-0400).
32. Reed LJ, Muench HA. A simple method of estimating fifty percent endpoints. Am J Hyg 1938;27:493-7